By analyzing E. coli protein levels, scientists found a surplus of membrane shuttle proteins that may play a role in antibiotic resistance.

Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...

AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.

A Cornell University-led collaboration has uncovered the equipment that enables bacteria to survive exposure to antibiotics: ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Gram-negative bacteria, such as E. coli, are common culprits in sepsis because they release LPS when they invade the bloodstream. These antibodies, created at OHSU, have already been tested in early ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...